Toronto Dominion Bank increased its position in shares of CVS Health Corp (NYSE:CVS) by 8.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 460,615 shares of the pharmacy operator’s stock after buying an additional 35,197 shares during the quarter. Toronto Dominion Bank’s holdings in CVS Health were worth $37,467,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in CVS. FMR LLC raised its holdings in CVS Health by 22.0% during the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock worth $2,425,920,000 after purchasing an additional 5,446,930 shares in the last quarter. Boston Partners raised its holdings in CVS Health by 69.1% during the second quarter. Boston Partners now owns 6,459,237 shares of the pharmacy operator’s stock worth $519,711,000 after purchasing an additional 2,638,888 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in CVS Health by 71.5% during the second quarter. Parametric Portfolio Associates LLC now owns 3,949,854 shares of the pharmacy operator’s stock worth $317,805,000 after purchasing an additional 1,647,168 shares in the last quarter. Prudential Financial Inc. raised its holdings in CVS Health by 61.8% during the second quarter. Prudential Financial Inc. now owns 2,946,531 shares of the pharmacy operator’s stock worth $237,078,000 after purchasing an additional 1,125,400 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in CVS Health by 8.4% during the second quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock worth $1,138,905,000 after purchasing an additional 1,100,373 shares in the last quarter. 81.69% of the stock is currently owned by hedge funds and other institutional investors.
In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.61% of the company’s stock.
CVS Health (NYSE:CVS) last posted its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. During the same period in the previous year, the company posted $1.64 EPS. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. equities analysts anticipate that CVS Health Corp will post 5.89 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s payout ratio is 41.32%.
CVS has been the topic of several recent analyst reports. Leerink Swann reissued an “outperform” rating and set a $85.00 target price (down previously from $90.00) on shares of CVS Health in a report on Tuesday, November 7th. Oppenheimer restated a “buy” rating and issued a $95.00 price target on shares of CVS Health in a research report on Monday, October 9th. Raymond James Financial upgraded shares of CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 price target on the stock in a research report on Thursday, January 4th. They noted that the move was a valuation call. SunTrust Banks set a $85.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research report on Thursday, October 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of CVS Health in a research report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. CVS Health presently has an average rating of “Buy” and an average target price of $86.66.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.